Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psychiatrist.com
High functioning depression is an oversimplified label for someone who effectively hides their persistent depression and seems to be managing their life well. The proper diagnosis is probably dysthymia. Dysthymia is difficult to detect until it intensifies into a major depressive episode. Asking questions about mood, sleep, medication and duration of depressive symptoms can help the clinician achieve a proper diagnosis.
Psychiatry January 10th 2023
Clinical Advisor
This overview and discussion highlights the learnings gleaned during practice in a ketamine service unit. Discussion points include treatment considerations for the two entities, switching from IV to intranasal, and a collection of pearls.
Psychiatry November 8th 2022
JAMA Network
Folic acid (B9) prescription in a population of more than 800,000 individuals, yielded a suicide event rate of 4.73 per 100 000 person-months, compared with a rate of 10.61 per 100 000 person-months without folic acid.
Psychiatry October 7th 2022
MDLinx
This report on learnings shows that it is crucial to educate primary healthcare professionals on how to spot people who may commit suicide in their later years (eg, using “The 5 Ds” — Deadly methods, Depression, Disease & Disability, Disconnectness, and Development) and how to adopt prevention measures.
Geriatrics September 19th 2022
SI, sadness, and anxiety symptoms could all be effectively treated with ketamine. The high rates of response and remission in population samples of TRD were comparable to those for interventional therapies. Racemic ketamine infusion as the main treatment for SI requires randomized controlled trials and comparative efficacy studies with other therapies.
Psychiatry September 19th 2022
Psych Congress Network
In what is thought to be the largest study to date of any type of ketamine treatment, the findings revealed that, after four sessions, 89 percent of participants reported improvement in their depression and/or anxiety symptoms. On the PHQ-9 or GAD-7 scale, 63 percent of participants saw a 50% or greater improvement. PHQ-9 remission rates were 32.6 percent and GAD-7 remission rates were 31.3 percent. Furthermore, at the end of the four weeks, 62 percent of patients who had suicidal ideation prior to treatment reported no suicidal ideation.
Psychiatry August 8th 2022